Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kristian Shearsby
Kristian Shearsby
Special Counsel
London +44 20 7067 2394 kshearsby@cov.com Download V-card

Kristian Shearsby is a special counsel in the Corporate Practice Group and is resident in Covington's London office. Mr. Shearsby advises on a wide range of matters, including mergers and acquisitions, private financings, and public offerings. Mr. Shearsby acts for companies at all stages of development, as well as investors and management teams. He has particular expertise in advising on deals in the life sciences and technology industries.

Corporate

  • Advised Oxford BioMedica plc, a London Stock Exchange listed biopharmaceutical company, on its 2018 placing to raise approximately £20.5 million and in connection with a $55 million secured debt facility with Oaktree Capital Management - Strategic Credit Strategy.
  • Advised Horizon Discovery Group plc, a leading life sciences company that supplies research tools to organizations engaged in genomics research and the development of personalized medicines, on various corporate and commercial transactions including its U.S. $85 million acquisition of GE Healthcare Dharmacon, Inc. from General Electric Company and on Horizon's related £80 million follow-on financing to part-finance the acquisition and to raise working capital for the enlarged business.
  • Acted for Cenkos Securities plc, as NOMAD and broker to AIM listed FairFX Group plc, on its placing and open offer to raise approximately £26 million and related acquisition of CardOne.   
  • Advised Cantor Fitzgerald Europe and RBC Capital Markets as joint bookrunners on the £15 million follow-on financing structured as a placing by UK-based biopharmaceutical company, Mereo BioPharma Group plc.
  • Advised Vernalis plc, a leading commercial stage pharmaceutical company, on a number of corporate matters including its £40 million follow-on financing by way of an institutional placing of new shares.
  • Advised ReNeuron Group plc, a leading clinical stage stem cell therapy company on a number of financings including its £68.4 million follow-on financing by way of an institutional placing of new shares.
  • Advised Consort Medical plc, listed on the London Main Market, on its £230 million acquisition of Aesica Holdco Limited from Silverfleet Capital and related £260 million equity and debt financing.
  • Advised Canaccord Genuity Limited as NOMAD and broker to AIM listed EKF Diagnostics Holding plc on its £26 million fundraise by way of an accelerated book build and related acquisitions of U.S.-based Selah Genomics Inc. and Swedish-based DiaSpect Medical AB.
  • Represented the management team of the Foundry, in relation to HgCapital’s investment under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD).
  • Advised visual effects software company, The Foundry on its acquisition of Luxology LLC and various other corporate and commercial matters.
  • Advised Johnson & Johnson on the acquisition of XO1 Limited, an asset-centric biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
  • Advised Brave Bison Group plc (formerly Rightster Group plc) on multiple corporate transactions including two acquisitions and a placing of new shares.
  • Advised Johnson & Johnson on the sale of its vaccine manufacturing business in Solna, Sweden to Valneva, a French pharmaceutical company listed on Euronext, Paris.
  • Advised Vectura Group Plc, a product development company listed on the London Main Market, on its acquisition of German pharmaceutical company Activaero GmbH for a total consideration of €130 million (£108 million) and related £52 million fundraising.